Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. distributes pharmaceuticals and specialty products and manufactures and distributes medical, laboratory, home-health and direct-to-patient products and services. The company also operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions for healthcare customers.
Recurring company updates cover financial results and fiscal outlooks, dividend actions, share repurchases, debt activity, segment performance in Global Medical Products and Distribution, at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics. Other developments include biosimilars and advanced-therapy research reports, Actinium-225 production capacity for radiopharmaceutical applications, and board governance changes.
Suzanne Foster, president of org value="NYSE:CAH"Cardinal Health at-Home, joins Exo's board of directors following a successful $220 million Series C funding round. With her extensive experience in healthcare and medical devices, Foster is expected to enhance Exo's commercialization efforts, particularly as it launches innovative handheld ultrasound devices. Exo aims to improve healthcare accessibility and real-time diagnostics. Additionally, Exo has expanded its executive team with key leadership appointments to support its growth.
Cardinal Health (NYSE: CAH) has secured a $750,000 contract from the FDA for an 18-month study examining real-world evidence (RWE) in lymphoma treatment. The study, titled 'Assessment of a Novel Methodology for Endpoints Assessing Response to Lymphoma Treatment in Real-World Studies,' aims to compare real-world data (RWD) with central review standards in clinical trials. This initiative supports the FDA's increasing focus on RWE following the 21st Century Cures Act and seeks to improve patient outcomes through enhanced regulatory decision-making.
Cardinal Health (NYSE: CAH) announced a new range of cancer screening options in collaboration with FUJIFILM Healthcare and Polymedco. These options aim to address the significant decline in cancer screenings caused by the pandemic, which saw nearly 10 million screenings missed in the U.S. alone. The company now offers at-home testing for colon cancer, reducing barriers to early detection. Additionally, it provides solutions for liver cancer surveillance, critical for at-risk patients. Cardinal Health emphasizes the importance of accessible diagnostics to improve healthcare outcomes.
Journey Biosciences announced a collaboration with Cardinal Health's OptiFreight® Logistics to enhance kidney disease diagnostics for diabetes patients. This partnership aims to deliver the innovative NaviDKD diagnostic screening technology to healthcare providers, facilitating proactive management of Diabetic Kidney Disease (DKD). The deal focuses on improving logistics management, which is critical for timely diagnostics. Journey Biosciences seeks to transform diabetes care from reactive to proactive, emphasizing early detection and risk reduction.
Cardinal Health (NYSE: CAH) has expanded its Strategic Stock Solution, now serving nearly 40 hospitals and health systems nationwide, just a year after launch. This solution addresses challenges in pandemic preparedness by allowing health systems to order and store critical supplies, ensuring deliveries within 72 hours. Key features include inventory management using real-time analytics and significant logistical support. With a focus on enhancing supply chain resiliency, Cardinal Health aims to prepare medical facilities for future health emergencies, including the upcoming flu and RSV season.
Summary not available.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Cherokee Nation for approximately $75 million over 6.5 years. This agreement resolves ongoing litigation and allows the companies to focus on safe medication delivery. The settlement is part of broader negotiations with federally recognized Native American tribes, despite the companies disputing the allegations against them. The firms emphasize their commitment to addressing the opioid epidemic's impact on communities.
Cardinal Health (NYSE: CAH) will release its first-quarter financial results for fiscal year 2022 on November 9, prior to market opening. A webcast discussion will follow at 8:30 a.m. Eastern. Investors can access the webcast and presentation through the Investor Relations page. Replay of the presentation will be available until November 8, 2022. Cardinal Health is a key player in the healthcare sector, distributing pharmaceuticals and manufacturing medical products globally.
On September 20, 2021, Cardinal Health (NYSE: CAH) announced a goal to reduce Scope 1 and Scope 2 greenhouse gas emissions by 50% by 2030. This commitment aligns with the Paris Agreement's climate goals. The company also plans to validate its Scope 3 emissions targets through the Science-Based Targets initiative. Environmental highlights include powering its global headquarters with renewable energy and expanding its Total Waste Management initiative, achieving significant waste reduction. Cardinal Health aims to enhance diversity by increasing the representation of women and underrepresented groups by 2030.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) announced progress on the opioid claims settlement involving U.S. states and territories. As of August 21, 2021, 42 states, 5 territories, and Washington, D.C. have joined the settlement, allowing the process to move forward. This next phase includes a 120-day period for political subdivisions to join, ending January 2, 2022. If enough subdivisions participate, the settlement will take effect 60 days after that. The companies aim to focus on secure medication delivery while providing relief to affected communities.